Lytix Biopharma AS Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2017
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2017
Net Income	-73.23	-94.27	-87.9	-56.07	-48.08	-42.09	Upgrade
Depreciation & Amortization	0.98	0.92	0.96	0.92	0.45	-	Upgrade
Stock-Based Compensation	11.87	0.88	4.18	1.38	4.05	8.4	Upgrade
Other Operating Activities	-1.54	-1.5	-2.35	-1.35	-0.13	-0	Upgrade
Change in Accounts Receivable	6.78	-0.34	-6.04	-1.06	-1.51	0.47	Upgrade
Change in Accounts Payable	-2.04	23.94	-4.83	3.55	0.61	8.87	Upgrade
Operating Cash Flow	-57.18	-70.37	-95.97	-52.63	-44.61	-24.35	Upgrade
Capital Expenditures	-	-	-0.05	-0.15	-	-	Upgrade
Investment in Securities	-60.92	23.18	27.42	-50.61	-	-	Upgrade
Other Investing Activities	1.55	1.51	2.35	1.41	0.14	-	Upgrade
Investing Cash Flow	-59.38	24.69	29.73	-49.36	0.14	-	Upgrade
Long-Term Debt Repaid	-	-0.85	-0.94	-0.83	-0.42	-	Upgrade
Net Debt Issued (Repaid)	-0.85	-0.85	-0.94	-0.83	-0.42	-	Upgrade
Issuance of Common Stock	111.3	161.3	-	0.13	225.21	40	Upgrade
Other Financing Activities	-8.34	-11.34	-0	-0.06	-11.49	-	Upgrade
Financing Cash Flow	102.11	149.11	-0.94	-0.75	213.3	40	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-	-0	-	Upgrade
Net Cash Flow	-14.45	103.43	-67.19	-102.73	168.83	15.65	Upgrade
Free Cash Flow	-57.18	-70.37	-96.02	-52.78	-44.61	-24.35	Upgrade
Free Cash Flow Margin	-15167.37%	-632.05%	-2405.86%	-478.47%	-231.04%	-597.62%	Upgrade
Free Cash Flow Per Share	-0.84	-1.30	-2.40	-1.33	-1.34	-0.93	Upgrade
Cash Interest Paid	0.01	0.01	0	0.06	0	-	Upgrade
Levered Free Cash Flow	-29.59	-34.62	-66.3	-36.49	-26.43	-8.74	Upgrade
Unlevered Free Cash Flow	-29.45	-34.54	-66.27	-36.4	-26.39	-8.74	Upgrade
Change in Working Capital	4.74	23.6	-10.87	2.5	-0.9	9.35	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.